Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Venlafaxine XR Clear all
Completed Phase 4 Interventional Results available

Anxiety and Depression in Epilepsy: A Treatment Study

NCT03464383
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg, Referral to Psychiatry, Survey only
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

NCT00018902
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury

NCT00167856
View directory record Official record
Conditions
Neuropathic Pain, Pain, Spinal Cord Injuries
Interventions
Venalafaxine hydrochloride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 21, 2026, 10:49 AM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 4 Interventional

Sexual Functioning Study With Antidepressants

NCT00316160
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
45
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

Sertraline vs. Venlafaxine XR

NCT00179283
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
sertraline, venlafaxine XR
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI)
Drug · Other · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Effexor XR Drug Interaction Study

NCT00362271
View directory record Official record
Conditions
Healthy
Interventions
Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise

NCT02407704
View directory record Official record
Conditions
Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions
Venlafaxine XR, Aerobic Exercise, Lorazepam
Drug · Other
Lead sponsor
Kirk Erickson, PhD
Other
Eligibility
60 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

NCT01235338
View directory record Official record
Conditions
Healthy
Interventions
LDX + Venlafaxine XR, Venlafaxine XR + LDX
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 21, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

NCT01114698
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine XR, Placebo, JNJ26489112
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Arcadia, California • Escondido, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

NCT01418209
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance
Interventions
Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

NCT00735670
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Venlafaxine HCl, Placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)

NCT00892047
View directory record Official record
Conditions
Depression
Interventions
venlafaxine XR plus aripiprazole, venlafaxine plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 21, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 21, 2026, 10:49 AM EDT
Withdrawn Phase 4 Interventional

Anxiety and Depression in Epilepsy: A Pilot Treatment Study

NCT03522987
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 21, 2026, 10:49 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 21, 2026, 10:49 AM EDT